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Abstract: The success of antiretroviral treatment (ART) is threatened by the emergence of drug
resistance mutations (DRM). Since Brazil presents the largest number of people living with HIV
(PLWH) in South America we aimed at understanding the dynamics of DRM in this country. We
analyzed a total of 20,226 HIV-1 sequences collected from PLWH undergoing ART between 2008–
2017. Results show a mild decline of DRM over the years but an increase of the K65R reverse
transcriptase mutation from 2.23% to 12.11%. This increase gradually occurred following alterations
in the ART regimens replacing zidovudine (AZT) with tenofovir (TDF). PLWH harboring the K65R
had significantly higher viral loads than those without this mutation (p < 0.001). Among the two
most prevalent HIV-1 subtypes (B and C) there was a significant (p < 0.001) association of K65R
with subtype C (11.26%) when compared with subtype B (9.27%). Nonetheless, evidence for K65R
transmission in Brazil was found both for C and B subtypes. Additionally, artificial neural network-
based immunoinformatic predictions suggest that K65R could enhance viral recognition by HLA-B27
that has relatively low prevalence in the Brazilian population. Overall, the results suggest that
tenofovir-based regimens need to be carefully monitored particularly in settings with subtype C and
specific HLA profiles.
Keywords: HIV-1; drug resistance mutations; K65R; antiretroviral treatment failure; tenofovir;
Brazilian cohort study
1. Introduction
According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), 690,000
individuals died in 2019 of human immunodeficiency virus (HIV) infection-related causes.
Although the global number of new infections (1.7 million) has been reduced by 23%,
since 2010, Latin America has presented a 21% increase. Particularly, Brazil experienced an
increase of 17%, with 48,000 new reported infections and 14,000 acquired immunodeficiency
syndrome (AIDS)-related deaths, in the same year [1].
Antiretroviral therapy (ART) significantly improves patients’ survival, increasing life
expectancy and quality [2–4]. Furthermore, it plays a relevant role in the prevention of
HIV-1 transmission in the population [5–8]. However, the emergence of drug resistance
mutations (DRM) represents a major threat for the continued control of HIV replication,
and consequent potential increase in the transmission of viral strains with DRM [9,10].
The prevalence of DRM can greatly vary between different geographical areas, depending
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on several factors, ranging from study design to the sociodemographic characteristics of
the population and most prevalent HIV-1 subtypes [9,11–15]. With a total area as vast as
8.51 million km2, different DRM rates have also been found in distinct Brazilian geographic
regions [9,12,16–20].
In 1996, Brazil became the first middle-income country to ensure free access to ART
to all individuals infected with HIV, through the public Unified Health System [21,22].
Currently, 69% of the people living with HIV are under ART [1]. Initial ART regimens
in Brazil consist of a combination of three drugs, comprising two NRTIs and a third of
different ART class: a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease
inhibitor (PI) or an integrase inhibitor (INSTI) [21]. Although pre-treatment testing for
DRM in the reverse transcriptase (RT) and protease (PR) has been widely recommended by
the International Antiviral Society–USA, the US Department of Health and Human Services
and the European AIDS Clinical Society, among others, viral genotyping and resistance
testing are preferably performed in Brazil after 6 months of treatment failure [21,23–25].
After 2013, pre-treatment genotyping was also indicated by the Brazilian Government in
the following scenarios: Mycobacterium tuberculosis (Mtb) co-infection, pregnant woman,
children and new diagnoses with a sexual partner under ART [21,22]. Importantly, Brazil is
the only country in South America that provides pre-exposure prophylaxis (PrEP) through
the public health system [1,21].
Among the surveillance drug-resistance mutations (SDRM) [26], K65R is commonly
associated with tenofovir (TDF) resistance and different prevalence rates of this mutation
have been reported in several Brazilian cities [11,17,27]. It was also associated with resis-
tance to other reverse transcriptase inhibitors (NRTIs), but it confers increased susceptibility
to zidovudine (AZT) [28–33]. K65R is acquired in B and several other HIV-1 subtypes by
the AAA→AGA substitution while in subtype C the involved substitution is AAG→AGG,
which has been associated with higher probability of C subtype viruses to acquire this
mutation [31,32,34,35].
The relevant reforms made in ART protocols in Brazil during the last decades, pro-
moting the preferential use TDF containing schemes in the absence of universal HIV-1
genotyping, raised the hypothesis that the HIV DRM profile could have changed, bringing
novel treatment obstacles and clinical implications. To test this hypothesis, we retrospec-
tively studied data from 20,226 HIV-1 infected and ART-treated individuals from all regions
of Brazil, from 2008 to 2017. We used statistical and genome sequence analysis to under-
stand, at an unprecedented scale in Brazil, the dynamics of evolution of the HIV-1 drug
resistance profiles. Additionally, we also relied on immunoinformatics to investigate factors
possible underlying treatment failure and transmission of DRM.
2. Results
2.1. Characterization of the Study Population
The study comprised a total of 20,226 HIV-1 infected individuals, with a HIV-1 se-
quence genotyped between 2008 and 2017, on ART treatment, from which 44.3% (n = 8962)
were female and 55.7% (n = 11,263) male. The main characteristics of the study population
are shown in Table 1. The median age was 39.55 (±12.71) years (yrs). Most of the individ-
uals were were between 30 and 49 yrs old (61.44%), from the State of São Paulo (21.98%;
n = 4445), followed by the States of Rio Grande do Sul (11.96%; n = 2419), Minas Gerais
(9.29%; n = 1878), Rio de Janeiro (9.20%; n = 1861) and Paraná (7.94%; n = 1606). The geo-
graphic frequency distribution for PLWH in the study population was in agreement with
the official Brazilian HIV-1 prevalence reports [36]. These patients were on ART, in average,
for 2.98 (±2.96) yrs and the most common treatment schemes combinations were: lamivu-
dine (3TC)/efavirenz (EFV)/TDF (21.38%; n = 4324), 3TC/AZT/EFV (19.79%; n = 4003),
3TC/AZT/low-dose ritonavir-boosted lopinavir (LPV) (11.16%; n = 2258), 3TC/LPV/TDF
(8.24%; n = 1666) and 3TC/atazanavir (ATV)/ritonavir (RTV)/TDF (6.70%; n = 1355).
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Table 1. Characterization of the study population.
HIV-1+ Individuals Female Male
All ages 20,226 (100.00%) 8962 (44.3%) 11,263 (55.7%)
<1 yrs old 64 (0.32%) 30 (0.15%) 34 (0.17%)
2–9 yrs old 364 (1.80%) 200 (0.99%) 164 (0.81%)
10–17 yrs old 840 (4.15%) 426 (2.11%) 414 (2.05%)
18–30 yrs old 2443 (12.08%) 1201 (5.94%) 1242 (6.14%)
30–49 yrs old 12,426 (61.44%) 5390 (26.65%) 7036 (34.79%)
50–79 yrs old 4074 (20.14%) 1709 (8.45%) 2364 (11.69%)
>80 yrs old 15 (0.07%) 6 (0.03%) 9 (0.04%)
Age (av. yrs ± std) 39.55 ± 12.71 38.67 ± 13.15 40.25 ± 12.31
Treatment (av. yrs ± std) 2.98 ± 2.96 3.06 ± 2.96 2.92 ± 2.95
Birth Federative Unit HIV-1+ individuals Treatment Scheme HIV-1+ individuals
São Paulo 4445 (21.98%) 3TC,EFV,TDF 4324 (21.38%)
Rio Grande do Sul 2419 (11.96%) 3TC,AZT,EFV 4003 (19.79%)
Minas Gerais 1878 (9.29%) 3TC,AZT,LPV 2258 (11.16%)
Rio de Janeiro 1861 (9.20%) 3TC,LPV,TDF 1666 (8.24%)
Paraná 1606 (7.94%) 3TC,ATV,RTV,TDF 1355 (6.70%)
Others 8017 (39.64%) Others 6620 (32.73%)
av. average; std, standard deviation; yrs, years; HIV-1+, HIV-1 infected.
2.2. Prevalence of Surveillance Drug-Resistance Mutations
We evaluated the presence of surveillance drug-resistance mutations (SDRM) in the
study population, including SDRM found isolated or in combinations in the same virus, and
uncovered an overall prevalence of 84.10% (n = 17,011). SDRM were mostly found at the RT
(83.24%; n = 16,836) and included 13,845 sequences with NRTI DRM and 11,720 sequences
with NNRTI DRM. The most common SDRM (Figure 1, Supplementary Table S2) were the
substitutions in RT amino acids M184V (65.53%, n = 13,265), K103N (40.20%, n = 8738), and
M41L (17.21%, n = 3480). SDRM in PR were found in 5021 (24.82%) sequences and the more
frequent were V82A (9.99%, n = 2021), M46I (9.58%, n = 1938), and I54V (8.50%, n = 1719).
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2.3. A Gradual Alteration on the Prevalence of Surveillance Drug-Resistance Mutations
To investigate the temporal dynamics and evolution of the SDRM landscape in the
study population we evaluated yearly SDRM prevalence from 2008 until 2017. The most
common mutation across the years was M184V (Figure 1), notwithstanding a decreasing
trend and a significant decrease between 2015 (68.29%, n = 1874) and 2016 (53.21%, n = 2684)
(p < 0.001) (Table 2). Similarly, all the other 10 most frequent SDRM followed a decreasing
trend along the years with the remarkable exception for K65R and K103N (Figure 1). K103N
remained stable in the studied period. While the prevalence of viruses harboring K103N
increased between 2014 (40.97%, n = 1180) and 2015 (47.12%, n = 1293; p < 0.001) this
was accompanied with a significant decrease in 2016 (42.53%, n = 2145; p < 0.001) and
no significant difference between 2008 and 2017 (p = 0.919). Importantly, K65R showed
a clear rise along the years (Figure 1). In 2008, the mutation was relatively rare and
only found in 2.23% (n = 8) of the population. Subsequently, this mutation became more
prevalent and increased significantly between 2013 and 2015 (p < 0.001). Although its
prevalence suffered a decrease between 2015 and 2016 (p = 0.0124), K65R prevailed the
third most common SDRM in 2016 and 2017 (Figure 1). Overall, the data strongly supports
that, in contrast with other prevalent SDRM, K65R prevalence was increasing in Brazil,
raising additional concerns about the efficacy of some of the ART combinations used.
In line with this hypothesis was the finding that viral loads for PLWH with K65R were
significantly higher than for the rest of the cohort (180,739.60 ± 497,000.10 cop/mL vs.
95,358.26 ± 338,930.67 cop/mL, respectively; p < 0.001).
Table 2. Yearly distribution of the most prevalent surveillance drug-resistance mutations in HIV-1 RT and PR.
2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 **
M184V 276 (76.88) 416 (73.37) 375 (75.45) 1076 (75.3) 1781 (72.46) 2082 (71.94) 2004 (69.58) 1874 (68.29) 2684 * (53.21) 697 (51.48)
K103N 149 (41.5) 252 (44.44) 217 (43.66) 638 (44.65) 1083 (44.06) 1215 (41.98) 1180 (40.97) 1293 * (47.12) 2145 * (42.53) 566 (41.8)
M41L 125 (34.82) 182 (32.1) 155 (31.19) 383 (26.8) 561 * (22.28) 585 * (20.21) 425 * (14.76) 374 (13.63) 545 * (10.8) 145 (10.71)
D67N 114 (31.75) 163 (28.75) 149 (29.98) 337 * (23.58) 504 * (20.5) 487 * (16.83) 435 (15.1) 398 (14.5) 526 * (10.43) 140 (10.34)
T215Y 109 (30.36) 144 (25.4) 141 (28.37) 299 * (20.92) 403 * (16.4) 434 (15) 323 * (11.22) 277 (10.09) 336 * (6.66) 72 (5.32)
K70R 96 (26.74) 133 (23.46) 131 (26.36) 308 * (21.55) 451 * (18.35) 459 * (15.86) 368 * (12.78) 344 (12.54) 460 * (9.12) 116 (8.57)
V82A 82 (22.84) 111 (19.58) 91 (18.31) 206 * (14.42) 335 (13.63) 313 * (10.82) 251 * (8.72) 242 (8.82) 303 * (6.01) 87 (6.43)
M46I 81 (22.56) 122 (21.52) 89 (17.91) 207 (14.49) 302 (12.29) 302 * (10.44) 222 * (7.71) 207 (7.54) 324 (6.42) 82 (6.06)
L210W 75 (20.89) 109 (19.22) 96 (19.32) 204 * (14.28) 294 * (11.96) 301 (10.4) 199 * (6.91) 172 (6.27) 249 * (4.94) 66 (4.87)
I54V 73 (20.33) 115 (20.28) 79 (15.9) 191 (13.37) 269 * (10.94) 273 (9.43) 224 * (7.78) 196 (7.14) 241 * (4.78) 58 (4.28)
G190A 46 (12.81) 80 (14.11) 47 * (9.46) 146 (10.22) 239 (9.72) 266 (9.19) 271 (9.41) 259 (9.44) 392 * (7.77) 102 (7.53)
P225H 36 (10.03) 56 (9.88) 62 (12.47) 179 (12.53) 320 (13.02) 403 (13.93) 370 (12.85) 390 (14.21) 586 * (11.62) 158 (11.67)
K65R 8 (2.23) 21 (3.7) 23 (4.63) 74 (5.18) 161 (6.55) 194 (6.7) 246 * (8.74) 374 * (13.63) 589 * (11.68) 164 (12.11)
Percentage number under parentheses. * A statistical difference was found with data from the previous year (p < 0.05). ** Data for 2017 was
only available Jan–Apr.
2.4. A Shift on Treatment Scheme during the Years
Having observed the clear increase in K65R along the studied yrs, we then decided to
evaluate the ART combination schemes in use during the studied period (Figure 2), aiming
at understanding ART usage impact on the SDRM. In 2008, from a total of 359 patients,
the most prevalent ART combination was 3TC/AZT/EFV (20.06%, n = 72), followed by
3TC/AZT/LPV (8.36%, n = 30), prevailing the most common treatment till 2014 (25.03%,
n = 721) among 2880 patients. From 2015 forward, 3TC/EFV/TDF scheme became the
most prevalent. In this year (n = 2744), 24.85% (682) individuals were under 3TC/EFV/TDF
drug combination and 19.97% (n = 548) under 3TC/AZT/EFV. In 2017, 3TC/EFV/TDF
combination was used on 40.10% (n = 543) of the individuals on ART (n = 1354).
As we have found a shift on the ART treatment scheme during the studied years,
we decided to evaluate SDRM prevalence separating the individuals using the most com-
mon drug combinations, 3TC/EFV/TDF (21.38%, n = 4324) and 3TC/AZT/EFV (19.79%,
n = 4003) (Figure 3). The SDRM with most similar prevalence when comparing both groups
were M46I, V82A, L90M and I54V. In contrast, K65R was only found in 0.37% (n = 15) of
the viruses isolated from patients treated with 3TC/AZT/EFV vs. 30.64% (n = 1325) of
the viruses from individuals using 3TC/EFV/TDF. This strong association of K65R with
TDF containing schemes was found across HIV-1 subtypes (Supplementary Figure S1).
Focusing on 2015, the year where the number of patients (n = 2744) using the two schemes
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was more even (3TC/AZT/EFV: 19.97%, n = 548; vs. 3TC/EFV/TDF: 24.85%, n = 682),
5 patients (0.91%) treated with 3TC/AZT/EFV were infected with a K65R mutant, being
this number significantly different (p < 0.001) from the 267 patients (39.15%) treated with
3TC/EFV/TDF combination. Also, comparing all patients revealed a significant association
between 3TC/EFV/TDF and K65R (p < 0.001).
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2.5. Evidence for Transmission of K65R
To investigate if the transmission of virus harboring K65R could have contributed
to the increase in the prevalence of this mutation in Brazil, we performed a phylogenetic
analysis on a subset of viral sequences including all the sequences with the K65R mutation
and closely related sequences from public databases (Supplementary Figures S2 and S3).
The definition of transmission clusters was performed as previously [37] considering tree
branch statistical support and mean genetic distance criteria. We found K65R in at least two
HIV-1 sequences in 21 well-delimited transmission clusters (16 from subtype B and 5 from
subtype C) (Supplementary Table S1). The size of the inferred transmission clusters ranged
from three to 16 individuals. The minimum spanning network analysis of these clusters
(Figure 4) supports the occurrence of events of K65R transmission in the study cohort.
Furthermore, the analysis of the clinical records from the individuals likely involved in
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K65R transmission supports this possibility for several cases showing a coincidence of
geographic location, proximity in diagnostic dates and similar reported transmission routes
(Supplementary Table S1). Despite the significant increased prevalence of the K65R in
subtype C (11.26%, n = 347) viruses when compared with B (9.27%, n= 1305) subtype
(p < 0.001, Supplementary Figure S2) we found probable events of K65R transmission also
in subtype B viruses.
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We then used an immunoinformatic approach to investigate the predicted impact
of K65R on immune-driven selective pressures. We performed artificial neural network-
based predictions of binding to the globally most frequent class I HLAs of all the peptide
sequences overlapping K65R and ranging from eight to 12 amino acids with the mutant
or the wild-type residue. Interestingly, we found that K65R overlapping peptides were
predicted to be recognized by two HLAs (HLA-A03, HLA-B58) in the wildtype version
and by one additional HLA (HLA-B27) in the mutant version (Table 3). HLA-B27 has
the lowest prevalence (2.23%) in the Brazilian population of all the HLAs tested. Overall,
our results suggest that the presence of K65R mutation might contribute for the immune
control of the virus in individuals harboring HLA-B27 possibly decreasing its transmission
in populations with high prevalence of this HLA.
Table 3. K65R mutant strong binding affinity to most frequent HLAs.
WT SB Binding K65R SB Binding Allele Freq. in BR Pop.
HLA-A01 no no 9.21
HLA-A02 no no 25.94
HLA-A03 yes yes 9.26
HLA-A24 no no 10.00
HLA-A26 no no 3.35
HLA-B07 no no 6.92
HLA-B08 no no 5.12
HLA-B15 no no 9.08
HLA-B27 no yes 2.23
HLA-B39 no no 3.46
HLA-B40 no no 4.70
HLA-B58 yes yes 2.65
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3. Discussion
Acquired and transmitted DRM remain one of the major obstacles towards ART
efficacy and AIDS treatment. In case of Brazil, previous regional studies showed distinct
moderate patters of transmitted DRM prevalence [11,16,20,27,38], and high DRM rates in
patients receiving ART [17–19,27,39]. In this study, we aimed at understanding SDRM [26]
prevalence across the 27 Brazilian federative units focusing on 20,226 HIV-1 infected
patients under different ART schemes, with viral sequence genotyped between 2008 and
2017. In accordance to the Brazilian HIV-1 epidemiology report [36], our cohort was
composed mainly by male individuals (55.7%) and the majority of the patients’ age varied
between 30 and 49 years old (61.44%).
A high prevalence of SDRM was observed with 84.1% of the infected individuals
presenting at least one drug resistance mutation. Nonetheless, 68.5% of the genotyped
sequences had a SDRM to NRTIs, a value that represents a decrease to what was previously
reported in the literature [17–19,39,40], following a trend that has been described by Duani
et al. and Diaz et al. in previous years [17,40]. However, NNRTI resistance rates (57.95%)
did not follow the increasing trend reported by the same authors, presenting a similar
value to what has been found in previous works [18,40]. PI resistance mutations (24.82%)
also seem to follow the reported decreasing trend [17,40].
Also in line with previous studies is the finding of M184V (65.53%), K103N (40.20%),
and M41L (17.21%) as the most common SDRM [17,19,39,40]. M184V, the most prevalent,
is a NRTI mutation selected by 3TC and associated with impaired viral fitness and hy-
persensitization to other NRTI, including AZT and TDF [41–43]. Along with the most
common mutations, M184V rates presented a decrease over the yrs (76.88% in 2008 to
51.48% in 2017). This decrease on acquired DRM was also observed in other countries and
was hypothesized to be due to an improvement on treatment efficacy and also an increased
accessibility to ART which enhances patient adherence to therapy [44–46]. Moreover, in
Brazil, pretreatment genotyping has been extended to children living with HIV under
12 years of age, in case of Mtb co-infection, to pregnant woman and new diagnoses with a
sexual partner on ART, since 2013 [47], which may had an impact the on the SDRM general
decrease trend.
Nonetheless, it is important to highlight that the percentage of PLWH infected with a
virus harboring M148V remained very high and above 50% after 2013. Moreover, K103N
and P225H, both frequent NNRTI SDRM, remained stable over the yrs. K103N was
previously reported as one of the most commonly acquired SDRM in Brazil [17,18,39,40] in
association with the use of EFV [48]. P225H is also selected by EFV and generally occurs in
the presence of K103N, synergically increasing EFV resistance [48–50]. As for K65R, it is
selected by TDF and by other NRTI including abacavir (ABC) and 3TC, decreasing viral
susceptibility to most of these drugs [29,31,51].
Previous work reported that K65R mutation presented varied prevalence distribution
throughout time in different Brazilian regions [17,19,27]. Strikingly, in our nationwide work
in Brazil we found that K65R was the only SDRM that followed an accentuated increase in
prevalence over the studied years (2.23% in 2008 to 12.11% in 2017). The increasing and pref-
erential usage of TDF in the clinical practice [21], including in a context of a failing regimen,
could be the primordial reason for the significant expansion of K65R as other studies show
a higher prevalence of this mutation in patients failing ART treatment [15,52–55]. However,
although an increasing trend was identified in a cohort from India [56], several studies
report a decrease on K65R levels over the years in other countries [48,57–60]. Reinheimer
and colleagues suggest that the decline on K65R prevalence rates is linked with the increas-
ing usage of single tablet ART regimens and the inclusion of AZT on the used treatment
regimen, which has been liked with K65R development suppression [61]. Moreover, Theys
et al. work [59] suggests that the found decline of tenofovir K65R selection rate in Portugal,
between 2002 and 2010, is mainly caused by changes on treatment guidelines over the
years and by the increased usage of combination of TDF and emtricitabine (FTC) [59].
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Collectively, these studies suggest that the genetic or sociodemographic characteristics of
the population treated with TDF might be influencing the K65R levels.
In 2019, 15.074 individuals were reported to use PrEP in Brazil [1]. Although PrEP
consists of a co-formulation of FTC and TDF [62], evidence suggests that the risk of
selection for TDF resistance is low and is more likely to occur in cases of undiagnosed
HIV infection [63,64]. However, in these cases, high prevalence rates of M184V, which is
also selected by FTC, and K65R as found in our study population, might compromise the
efficacy of PrEP [65,66].
K65R has been associated with diminished viral fitness and replication, which has
been linked with decreased transmission capacity [67,68]. Even though several studies
support almost inexistent K65R transmission rates [11,69,70], Rhee and co-works present
evidence of higher levels of transmitted K65R, especially in low- and middle-income
countries [71]. In our phylogenetic analysis we found 21 transmission clusters containing
at least two sequences with the K65R mutation. Moreover, minimum spanning network
analysis supported the occurrence of events of K65R transmission in at least seven of
these clusters. This might be suggestive that the efficacy of PrEP might be compromised
in this setting. Indeed, we found much higher viral loads in patients harboring K65R
mutation when compared with the rest of our cohort population. Similar viral loads were
observed between individuals with and without tenofovir resistance by The TenoRes Study
Group [72], which can be associated with increased mutation transmission. Furthermore,
our results suggest that K65R overlapping peptides can be increasingly recognized by
HLA-B27, a HLA that is linked with lower viral loads and slower diseased progression
to AIDS [73,74]. The fact that Brazil presents a low prevalence of the HLA-B27, when
in comparison with other regions [75–77], might have contributed to K65R expansion in
this country. However, it is relevant to point-out that our results are based on in-silico
prediction and not taking in consideration the possible impact on immune responses of the
combination of different mutations in the same virus. Thus, it is relevant to address this
topic in the future by performing functional studies.
Despite of the observed decreasing trend in the prevalence of some major SDRM in
the studied Brazilian cohort, a high prevalence of these mutations was still verified. Indeed,
our results show that the alteration performed in 2013 enlarging the criteria to include more
PLWH in the recommendation for baseline SDRM testing had a positive impact but was
still insufficient. We propose that the lack of universal baseline HIV-1 DRM screening to
inform on effective ART regimens resulted in high levels of SDRM, such as M184V, K103N,
and M41L underlying many cases of treatment failure in Brazil not only from 2008–2012
but also continuing from 2013–2017. Furthermore, we observed a clear increase in K65R
reverse transcriptase SDRM that is an additional problem in Brazil that could have been
aggravated by the circulation of HIV-1 subtype C and the HLA class I makeup of the
population. This increase in K65R was mainly found in association with the use of TDF
and is particularly relevant in combination with the high M184V levels found in the study
population suggesting that the efficacy of PrEP might be compromised.
Overall, our results support that some of the drugs most frequently used in Brazil
might be compromised due to the high frequency of SDRM and that baseline drug resistance
testing should be universal and mandatory as it is the best way to promote personalized
selection of the most optimized ART regiment.
4. Materials and Methods
4.1. Study Population
The collection of the patient’s data was performed anonymously after approval by the
Brazilian national ethic committee through the protocol CAAE 53757016.0.0000.5504. All
records from HIV-1-infected individuals followed by the Specialized Assistance Services
on Sexually Transmissible Diseases and HIV/AIDS obtained at all 27 Brazilian federative
units from 01/01/2008 to 04/30/2017 were curated in a relational database. A total of
20,226 HIV-1 infected patients were selected for this study according to the following
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inclusion criteria: (i) be under ART treatment; (ii) have at least one associated partial
HIV-1 genome sequence available (complete HIV protease (n = 20,223) and complete
reverse transcriptase (n = 20,214)). HIV-1 sequencing was performed as part of the routine
clinical testing with commercially available HIV-1 genotyping systems based on Sanger
sequencing.
4.2. HIV-1 Subtypes and Drug Resistance Mutations
HIV-1 subtypes were identified by relying on the consensus from least two of the three
utilized subtyping tools: SNAPPY [78], jpHMM [79] and Stanford HIV Drug Resistance
database (https://hivdb.stanford.edu/, accessed on 1 May 2021). All sequences were also
analyzed using the Stanford HIVdb Genotypic Resistance Interpretation Algorithm to
evaluate and interpret the presence of DRM in each sequence.
4.3. Phylogenetic Analysis of K65R Sequences and Transmission Clusters
All sequences having the K65R were separated by subtype and used to query local
and public databases to identify highly related HIV-1 sequences. The resulting sequences
from the most common subtypes B and C were aligned with MAFFT v7.309 [80] and used
to make a phylogenetic reconstruction using PhyML v3.0 [37]. The best fitting substitution
model was GTR + G4 + I, determined by PhyML SMS using AIC [81]. The heuristic trees
search was performed using SPR methods. Bayesian evolutionary analyses were performed
using BEAST v1.10.4 [82,83] with GTR + G4 + I, as the nucleotide substitution model. This
phylogenetic representation was used to infer the transmission clusters as previously [84].
Minimum spanning network analysis of the sequences identified in transmission clusters
with more than one K65R mutant was performed with PHYLOViZ [85].
4.4. HLA Binding Affinity Predictions
Predictions of binding for different class 1 human leukocyte antigens (HLA) were
performed with NetMHCpan 4.1 [86]. The wildtype sequence (NPYNTPVFAIKKKDSTK-
WRKLVD) and the sequence with the K65R mutation (NPYNTPVFAIKRKDSTKWRKLVD)
were used to generate all possible peptides sequences overlapping position 65 and ranging
from eight to 12 amino acids. A group of 11 HLAs were used as supertype representatives:
HLA-A01:01; HLA-A02:01; HLA-A03:01; HLA-A24:02; HLA-A26:01; HLA-B07:02; HLA-
B08:01; HLA-B27:05; HLA-B39:01; HLA-B40:01; HLA-B58:01; HLA-B15:01. The thresholds
for the definition of binding were maintained as the tool defaults, only binding results
classified as “strong binding” were considered.
4.5. HLA Prevalence in the Brazilian Population
The Allele Frequencies Database [87] was used as the source of this information for
the Brazilian population. To obtain cohesive and yet representative nationwide results,
the bone marrow registry (REDOME) data was selected. Since this data is separated by
Brazilian state, we calculated the proportional values for a national level estimation.
4.6. Statistical Analysis
Statistical analysis was performed by using Epi Info™ version 7.2.4.0 (https://www.
cdc.gov/epiinfo/index.html, accessed on 1 May 2021), relying on Mantel-Haenszel test, at
significance level of 0.05, to evaluate statistical correlations. SPSS® Statistics version 26.0
(IBM®, Armonk, NY, USA) was also utilized for performing mean comparison with t-test,
at a 0.05 significance level.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/ijms22105304/s1, Figure S1: Presence of SDMR among subtypes, Figure S2: Phylogenetic
representation of a subset of HIV-1 subtype C sequences isolated in Brazil with the K65R mutation
and closely related sequences from databases, Figure S3: Phylogenetic representation of a subset of
HIV-1 subtype B sequences isolated in Brazil with the K65R mutation and closely related sequences
from databases. Table S1: Phylogeny inferred HIV-1 transmission clusters with more than one
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sequences harboring the K65R mutation, Table S2: Top SDRM on different Brazilian Regions through
the years.
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